Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) Daratumumab

N/AApproved For MarketingNCT04264884

Janssen Research & Development, LLC

Overview

The purpose of this pre-approval access (PAA) program is to provide treatment to participants with serious/life-threatening diseases or conditions.

Study Type

EXPANDED_ACCESS

Daratumumab 1800 milligram (mg) will be administered as a fixed dose by subcutaneous (SC) injection.

Medical Language ↔ Plain English

Inclusion Criteria: \- Exclusion Criteria: \-

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.